Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 14/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 14/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 11/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 9/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13770949 | 0.78 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13780924 | 0.78 | PIK3CD (0.32) | — | |
| SCHEMBL11091699 | 0.74 | ALDH1A1 (0.32) | — | |
| SCHEMBL13780927 | 0.73 | ALDH1A1 (0.37) | — | |
| SCHEMBL2736112 | 0.71 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2760149 | 0.69 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22446850 | 0.69 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL12518263 | 0.67 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13780923 | 0.67 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL20860599 | 0.66 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759379-B2 | Inhibitors of cytochrome P450 | GILEAD SCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES, INC. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | CYP11B1, CYP11B2, CYP2F1 | CHRNB2 2946/4885CHRNA4 4243/4885CHRNB4 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.